カテゴリ： 世界, 医療/バイオ, QYResearch

出血性脳卒中治療薬の世界市場2023年：抗凝固剤、利尿剤、その他

■ 英語タイトル：Global Hemorrhagic Stroke Drugs Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8784）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8784
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：87
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[出血性脳卒中治療薬の世界市場2023年：抗凝固剤、利尿剤、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は出血性脳卒中治療薬のグローバル市場について調査・分析し、世界の出血性脳卒中治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（抗凝固剤、利尿剤、その他）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Novartis AG、Daiichi Sankyo Company、Zydus Cadila、F. Hoffmann-La Roche Ltd.、Boehringer Ingelheim International GmbH、Amneal Pharmaceuticals LLC、Teva Pharmaceutical Industries Ltd.、AstraZenica、Bristol-Myers Squibb Company、Johnson and Johnson Services, Inc.などが含まれています。出血性脳卒中治療薬のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、出血性脳卒中治療薬市場規模を算出する際に考慮しました。

・出血性脳卒中治療薬市場の概要
- 出血性脳卒中治療薬の種類別セグメント
- 世界の出血性脳卒中治療薬市場規模：タイプ別分析（抗凝固剤、利尿剤、その他）
- 出血性脳卒中治療薬の用途別セグメント
- 世界の出血性脳卒中治療薬市場規模：用途別分析（病院、薬局、その他）
- 世界の出血性脳卒中治療薬市場規模予測（2018年-2029年）

・出血性脳卒中治療薬市場の成長トレンド
- 出血性脳卒中治療薬の地域別市場規模（2018年-2029年）
- 出血性脳卒中治療薬市場ダイナミクス
- 出血性脳卒中治療薬の業界動向
- 出血性脳卒中治療薬市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：抗凝固剤、利尿剤、その他
- 世界の出血性脳卒中治療薬のタイプ別市場規模（2018年-2023年）
- 世界の出血性脳卒中治療薬のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、薬局、その他
- 世界の出血性脳卒中治療薬の用途別市場規模（2018年-2023年）
- 世界の出血性脳卒中治療薬の用途別市場規模（2024年-2029年）

・出血性脳卒中治療薬の地域別市場規模
- 北米の出血性脳卒中治療薬市場規模（2018年-2029年）
- 米国の出血性脳卒中治療薬市場規模（2018年-2029年）
- ヨーロッパの出血性脳卒中治療薬市場規模（2018年-2029年）
- アジア太平洋の出血性脳卒中治療薬市場規模（2018年-2029年）
- 中国の出血性脳卒中治療薬市場規模（2018年-2029年）
- 日本の出血性脳卒中治療薬市場規模（2018年-2029年）
- 韓国の出血性脳卒中治療薬市場規模（2018年-2029年）
- インドの出血性脳卒中治療薬市場規模（2018年-2029年）
- オーストラリアの出血性脳卒中治療薬市場規模（2018年-2029年）
- 中南米の出血性脳卒中治療薬市場規模（2018年-2029年）
- 中東・アフリカの出血性脳卒中治療薬市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Novartis AG、Daiichi Sankyo Company、Zydus Cadila、F. Hoffmann-La Roche Ltd.、Boehringer Ingelheim International GmbH、Amneal Pharmaceuticals LLC、Teva Pharmaceutical Industries Ltd.、AstraZenica、Bristol-Myers Squibb Company、Johnson and Johnson Services, Inc.

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Hemorrhagic Stroke Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Hemorrhagic Stroke Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Hemorrhagic Stroke Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Hemorrhagic Stroke Drugs in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Hemorrhagic Stroke Drugs include Novartis AG, Daiichi Sankyo Company, Zydus Cadila, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., AstraZenica and Bristol-Myers Squibb Company, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Hemorrhagic Stroke Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemorrhagic Stroke Drugs.
The Hemorrhagic Stroke Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Hemorrhagic Stroke Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hemorrhagic Stroke Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis AG
Daiichi Sankyo Company
Zydus Cadila
F. Hoffmann-La Roche Ltd.
Boehringer Ingelheim International GmbH
Amneal Pharmaceuticals LLC
Teva Pharmaceutical Industries Ltd.
AstraZenica
Bristol-Myers Squibb Company
Johnson and Johnson Services, Inc.
Segment by Type
Anticoagulant
Diuretics
Others
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hemorrhagic Stroke Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemorrhagic Stroke Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Anticoagulant
1.2.3 Diuretics
1.2.4 Others
1.3 Market by Application
1.3.1 Global Hemorrhagic Stroke Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemorrhagic Stroke Drugs Market Perspective (2018-2029)
2.2 Hemorrhagic Stroke Drugs Growth Trends by Region
2.2.1 Global Hemorrhagic Stroke Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hemorrhagic Stroke Drugs Historic Market Size by Region (2018-2023)
2.2.3 Hemorrhagic Stroke Drugs Forecasted Market Size by Region (2024-2029)
2.3 Hemorrhagic Stroke Drugs Market Dynamics
2.3.1 Hemorrhagic Stroke Drugs Industry Trends
2.3.2 Hemorrhagic Stroke Drugs Market Drivers
2.3.3 Hemorrhagic Stroke Drugs Market Challenges
2.3.4 Hemorrhagic Stroke Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemorrhagic Stroke Drugs Players by Revenue
3.1.1 Global Top Hemorrhagic Stroke Drugs Players by Revenue (2018-2023)
3.1.2 Global Hemorrhagic Stroke Drugs Revenue Market Share by Players (2018-2023)
3.2 Global Hemorrhagic Stroke Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hemorrhagic Stroke Drugs Revenue
3.4 Global Hemorrhagic Stroke Drugs Market Concentration Ratio
3.4.1 Global Hemorrhagic Stroke Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemorrhagic Stroke Drugs Revenue in 2022
3.5 Hemorrhagic Stroke Drugs Key Players Head office and Area Served
3.6 Key Players Hemorrhagic Stroke Drugs Product Solution and Service
3.7 Date of Enter into Hemorrhagic Stroke Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemorrhagic Stroke Drugs Breakdown Data by Type
4.1 Global Hemorrhagic Stroke Drugs Historic Market Size by Type (2018-2023)
4.2 Global Hemorrhagic Stroke Drugs Forecasted Market Size by Type (2024-2029)
5 Hemorrhagic Stroke Drugs Breakdown Data by Application
5.1 Global Hemorrhagic Stroke Drugs Historic Market Size by Application (2018-2023)
5.2 Global Hemorrhagic Stroke Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Hemorrhagic Stroke Drugs Market Size (2018-2029)
6.2 North America Hemorrhagic Stroke Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hemorrhagic Stroke Drugs Market Size by Country (2018-2023)
6.4 North America Hemorrhagic Stroke Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemorrhagic Stroke Drugs Market Size (2018-2029)
7.2 Europe Hemorrhagic Stroke Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hemorrhagic Stroke Drugs Market Size by Country (2018-2023)
7.4 Europe Hemorrhagic Stroke Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hemorrhagic Stroke Drugs Market Size (2018-2029)
8.2 Asia-Pacific Hemorrhagic Stroke Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hemorrhagic Stroke Drugs Market Size by Region (2018-2023)
8.4 Asia-Pacific Hemorrhagic Stroke Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hemorrhagic Stroke Drugs Market Size (2018-2029)
9.2 Latin America Hemorrhagic Stroke Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hemorrhagic Stroke Drugs Market Size by Country (2018-2023)
9.4 Latin America Hemorrhagic Stroke Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemorrhagic Stroke Drugs Market Size (2018-2029)
10.2 Middle East & Africa Hemorrhagic Stroke Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hemorrhagic Stroke Drugs Market Size by Country (2018-2023)
10.4 Middle East & Africa Hemorrhagic Stroke Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Detail
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Hemorrhagic Stroke Drugs Introduction
11.1.4 Novartis AG Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.1.5 Novartis AG Recent Development
11.2 Daiichi Sankyo Company
11.2.1 Daiichi Sankyo Company Company Detail
11.2.2 Daiichi Sankyo Company Business Overview
11.2.3 Daiichi Sankyo Company Hemorrhagic Stroke Drugs Introduction
11.2.4 Daiichi Sankyo Company Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.2.5 Daiichi Sankyo Company Recent Development
11.3 Zydus Cadila
11.3.1 Zydus Cadila Company Detail
11.3.2 Zydus Cadila Business Overview
11.3.3 Zydus Cadila Hemorrhagic Stroke Drugs Introduction
11.3.4 Zydus Cadila Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.3.5 Zydus Cadila Recent Development
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Company Detail
11.4.2 F. Hoffmann-La Roche Ltd. Business Overview
11.4.3 F. Hoffmann-La Roche Ltd. Hemorrhagic Stroke Drugs Introduction
11.4.4 F. Hoffmann-La Roche Ltd. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.4.5 F. Hoffmann-La Roche Ltd. Recent Development
11.5 Boehringer Ingelheim International GmbH
11.5.1 Boehringer Ingelheim International GmbH Company Detail
11.5.2 Boehringer Ingelheim International GmbH Business Overview
11.5.3 Boehringer Ingelheim International GmbH Hemorrhagic Stroke Drugs Introduction
11.5.4 Boehringer Ingelheim International GmbH Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.5.5 Boehringer Ingelheim International GmbH Recent Development
11.6 Amneal Pharmaceuticals LLC
11.6.1 Amneal Pharmaceuticals LLC Company Detail
11.6.2 Amneal Pharmaceuticals LLC Business Overview
11.6.3 Amneal Pharmaceuticals LLC Hemorrhagic Stroke Drugs Introduction
11.6.4 Amneal Pharmaceuticals LLC Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.6.5 Amneal Pharmaceuticals LLC Recent Development
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.7.3 Teva Pharmaceutical Industries Ltd. Hemorrhagic Stroke Drugs Introduction
11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.8 AstraZenica
11.8.1 AstraZenica Company Detail
11.8.2 AstraZenica Business Overview
11.8.3 AstraZenica Hemorrhagic Stroke Drugs Introduction
11.8.4 AstraZenica Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.8.5 AstraZenica Recent Development
11.9 Bristol-Myers Squibb Company
11.9.1 Bristol-Myers Squibb Company Company Detail
11.9.2 Bristol-Myers Squibb Company Business Overview
11.9.3 Bristol-Myers Squibb Company Hemorrhagic Stroke Drugs Introduction
11.9.4 Bristol-Myers Squibb Company Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.9.5 Bristol-Myers Squibb Company Recent Development
11.10 Johnson and Johnson Services, Inc.
11.10.1 Johnson and Johnson Services, Inc. Company Detail
11.10.2 Johnson and Johnson Services, Inc. Business Overview
11.10.3 Johnson and Johnson Services, Inc. Hemorrhagic Stroke Drugs Introduction
11.10.4 Johnson and Johnson Services, Inc. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023)
11.10.5 Johnson and Johnson Services, Inc. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Hemorrhagic Stroke Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Anticoagulant
Table 3. Key Players of Diuretics
Table 4. Key Players of Others
Table 5. Global Hemorrhagic Stroke Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 6. Global Hemorrhagic Stroke Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Hemorrhagic Stroke Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Hemorrhagic Stroke Drugs Market Share by Region (2018-2023)
Table 9. Global Hemorrhagic Stroke Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global Hemorrhagic Stroke Drugs Market Share by Region (2024-2029)
Table 11. Hemorrhagic Stroke Drugs Market Trends
Table 12. Hemorrhagic Stroke Drugs Market Drivers
Table 13. Hemorrhagic Stroke Drugs Market Challenges
Table 14. Hemorrhagic Stroke Drugs Market Restraints
Table 15. Global Hemorrhagic Stroke Drugs Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Hemorrhagic Stroke Drugs Market Share by Players (2018-2023)
Table 17. Global Top Hemorrhagic Stroke Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemorrhagic Stroke Drugs as of 2022)
Table 18. Ranking of Global Top Hemorrhagic Stroke Drugs Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Hemorrhagic Stroke Drugs Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Hemorrhagic Stroke Drugs Product Solution and Service
Table 22. Date of Enter into Hemorrhagic Stroke Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Hemorrhagic Stroke Drugs Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Hemorrhagic Stroke Drugs Revenue Market Share by Type (2018-2023)
Table 26. Global Hemorrhagic Stroke Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global Hemorrhagic Stroke Drugs Revenue Market Share by Type (2024-2029)
Table 28. Global Hemorrhagic Stroke Drugs Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Hemorrhagic Stroke Drugs Revenue Market Share by Application (2018-2023)
Table 30. Global Hemorrhagic Stroke Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global Hemorrhagic Stroke Drugs Revenue Market Share by Application (2024-2029)
Table 32. North America Hemorrhagic Stroke Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 33. North America Hemorrhagic Stroke Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Hemorrhagic Stroke Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 35. Europe Hemorrhagic Stroke Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. Europe Hemorrhagic Stroke Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Hemorrhagic Stroke Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Hemorrhagic Stroke Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 39. Asia-Pacific Hemorrhagic Stroke Drugs Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Hemorrhagic Stroke Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 41. Latin America Hemorrhagic Stroke Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 42. Latin America Hemorrhagic Stroke Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Hemorrhagic Stroke Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 44. Middle East & Africa Hemorrhagic Stroke Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Middle East & Africa Hemorrhagic Stroke Drugs Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Hemorrhagic Stroke Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 47. Novartis AG Company Detail
Table 48. Novartis AG Business Overview
Table 49. Novartis AG Hemorrhagic Stroke Drugs Product
Table 50. Novartis AG Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 51. Novartis AG Recent Development
Table 52. Daiichi Sankyo Company Company Detail
Table 53. Daiichi Sankyo Company Business Overview
Table 54. Daiichi Sankyo Company Hemorrhagic Stroke Drugs Product
Table 55. Daiichi Sankyo Company Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 56. Daiichi Sankyo Company Recent Development
Table 57. Zydus Cadila Company Detail
Table 58. Zydus Cadila Business Overview
Table 59. Zydus Cadila Hemorrhagic Stroke Drugs Product
Table 60. Zydus Cadila Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 61. Zydus Cadila Recent Development
Table 62. F. Hoffmann-La Roche Ltd. Company Detail
Table 63. F. Hoffmann-La Roche Ltd. Business Overview
Table 64. F. Hoffmann-La Roche Ltd. Hemorrhagic Stroke Drugs Product
Table 65. F. Hoffmann-La Roche Ltd. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 66. F. Hoffmann-La Roche Ltd. Recent Development
Table 67. Boehringer Ingelheim International GmbH Company Detail
Table 68. Boehringer Ingelheim International GmbH Business Overview
Table 69. Boehringer Ingelheim International GmbH Hemorrhagic Stroke Drugs Product
Table 70. Boehringer Ingelheim International GmbH Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 71. Boehringer Ingelheim International GmbH Recent Development
Table 72. Amneal Pharmaceuticals LLC Company Detail
Table 73. Amneal Pharmaceuticals LLC Business Overview
Table 74. Amneal Pharmaceuticals LLC Hemorrhagic Stroke Drugs Product
Table 75. Amneal Pharmaceuticals LLC Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 76. Amneal Pharmaceuticals LLC Recent Development
Table 77. Teva Pharmaceutical Industries Ltd. Company Detail
Table 78. Teva Pharmaceutical Industries Ltd. Business Overview
Table 79. Teva Pharmaceutical Industries Ltd. Hemorrhagic Stroke Drugs Product
Table 80. Teva Pharmaceutical Industries Ltd. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 81. Teva Pharmaceutical Industries Ltd. Recent Development
Table 82. AstraZenica Company Detail
Table 83. AstraZenica Business Overview
Table 84. AstraZenica Hemorrhagic Stroke Drugs Product
Table 85. AstraZenica Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 86. AstraZenica Recent Development
Table 87. Bristol-Myers Squibb Company Company Detail
Table 88. Bristol-Myers Squibb Company Business Overview
Table 89. Bristol-Myers Squibb Company Hemorrhagic Stroke Drugs Product
Table 90. Bristol-Myers Squibb Company Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 91. Bristol-Myers Squibb Company Recent Development
Table 92. Johnson and Johnson Services, Inc. Company Detail
Table 93. Johnson and Johnson Services, Inc. Business Overview
Table 94. Johnson and Johnson Services, Inc. Hemorrhagic Stroke Drugs Product
Table 95. Johnson and Johnson Services, Inc. Revenue in Hemorrhagic Stroke Drugs Business (2018-2023) & (US$ Million)
Table 96. Johnson and Johnson Services, Inc. Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hemorrhagic Stroke Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Hemorrhagic Stroke Drugs Market Share by Type: 2022 VS 2029
Figure 3. Anticoagulant Features
Figure 4. Diuretics Features
Figure 5. Others Features
Figure 6. Global Hemorrhagic Stroke Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Hemorrhagic Stroke Drugs Market Share by Application: 2022 VS 2029
Figure 8. Hospital Case Studies
Figure 9. Pharmacy Case Studies
Figure 10. Others Case Studies
Figure 11. Hemorrhagic Stroke Drugs Report Years Considered
Figure 12. Global Hemorrhagic Stroke Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Hemorrhagic Stroke Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Hemorrhagic Stroke Drugs Market Share by Region: 2022 VS 2029
Figure 15. Global Hemorrhagic Stroke Drugs Market Share by Players in 2022
Figure 16. Global Top Hemorrhagic Stroke Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemorrhagic Stroke Drugs as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Hemorrhagic Stroke Drugs Revenue in 2022
Figure 18. North America Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Hemorrhagic Stroke Drugs Market Share by Country (2018-2029)
Figure 20. United States Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Hemorrhagic Stroke Drugs Market Share by Country (2018-2029)
Figure 24. Germany Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Hemorrhagic Stroke Drugs Market Share by Region (2018-2029)
Figure 32. China Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Hemorrhagic Stroke Drugs Market Share by Country (2018-2029)
Figure 40. Mexico Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Hemorrhagic Stroke Drugs Market Share by Country (2018-2029)
Figure 44. Turkey Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Hemorrhagic Stroke Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Novartis AG Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 47. Daiichi Sankyo Company Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 48. Zydus Cadila Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 49. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 50. Boehringer Ingelheim International GmbH Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 51. Amneal Pharmaceuticals LLC Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 52. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 53. AstraZenica Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 54. Bristol-Myers Squibb Company Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 55. Johnson and Johnson Services, Inc. Revenue Growth Rate in Hemorrhagic Stroke Drugs Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 医療機器用機能コーティング剤のグローバル市場展望 2023年-2029年：親水性、抗菌性、抗凝固剤、その他
  • 血液腫瘍薬の世界市場2023年：化学療法、標的療法、免疫療法、その他
  • 世界の出血熱ワクチン市場2022年：市場規模予測（～2028年）
  • 脂肪肝治療薬の世界市場2023年：ALD、NAFLD
  • アドレナリン受容体遮断薬の世界市場2023年：アルファブロッカー、ベータブロッカー、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8784 )"出血性脳卒中治療薬の世界市場2023年：抗凝固剤、利尿剤、その他" (英文：Global Hemorrhagic Stroke Drugs Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。